SUBSCRIBE
SUBSCRIBE
News   FDA

Novo Nordisk A/S, AstraZeneca PLC-Bristol-Myers Squibb Company Diabetes Drugs Face U.S. Grilling

March 26, 2009 | 
1 min read

LONDON, March 26 (Reuters) - Two new diabetes drugs face tough appraisals from U.S. experts next week, promising a volatile ride for shares in Novo Nordisk, AstraZeneca and Bristol-Myers Squibb.

FDA Approvals Regulatory Europe
AstraZeneca Pharmaceuticals LP Bristol Myers Squibb Company Novo Nordisk
MORE ON THIS TOPIC
Chalk drawing arrow turn or break through road block traffic pylon on dark blackboard using as obstacle, solution for business problem or break through to success concept.
Antibody-drug conjugate (ADC)
GSK’s Comeback for Blenrep on Pause as FDA Delays Decision
July 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Baltimore, Maryland, skyline
Business
Maryland’s Life Sciences Scene Boasts Strong R&D, Manufacturing Talent
July 24, 2025
 · 
4 min read
 · 
Angela Gabriel
Job interview, recruitment concepts. Row of chairs with one odd one out. Job opportunity. Blue chair in spotlight. Business leadership. 3D Rendering
FDA
From Expertise to Empty Chairs: The FDA’s Self-Inflicted Crisis
July 23, 2025
 · 
7 min read
 · 
Lori Ellis
Department of Homeland Security (DHS) Secretary Kristi Noem tours the National Biodefense Analysis and Countermeasures Cetner with Health and Human Services Secretary Robert F. Kennedy, Jr. and U.S. Senator Rand Paul on Fort Detrick, Maryland, June 16, 2025. (DHS photo by Tia Dufour)
Vaccines
HHS To Remove Little-Used Thimerosal From All Influenza Vaccines
July 23, 2025
 · 
2 min read
 · 
Dan Samorodnitsky